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1 Introduction
A two-day Forum on Science and Technology 
Policy was held by the American Association for 
the Advancement of Science (AAAS)*1 on May 
3 and 4, 2007, in Washington, DC. This policy 
forum has been held every spring since 1976. This 
year’s was the 32nd[1]. (The name was changed 
from “colloquium” to “forum” beginning in 
2004.)
This policy forum differs from the large AAAS 
Annual Meeting where symposiums on a variety 
of themes are held. The number of sessions 
and themes are limited, and the forum takes 
up issues facing the US science and technology 
community, such as trends and areas of policy 
emphasis in Congressional debate on the science 
and technology budget and recent changes in 
status. It provides an important opportunity 
for scientists, relevant government officials etc. 
to meet together and discuss these issues with 
shared awareness.
This year, over 400 people par t icipated, 
including government officials such as John H. 
Marburger, III, Science Advisor to the President 
(and Director, White House Office of Science 
and Technology Policy), who attended for the 
sixth straight year; members of the legislative 
branch including Bart Gordon, Member, US 
House of Representatives (Democrat, Tennessee), 
chairman, House Committee on Science and 
Technology; university educators and researchers; 
researchers and analysts from relevant think 
tanks; members of relevant academic societies; 
and people involved with science and technology 
policy in other countries. The themes for this year 
were as follows[2].
Plenary Sessions
•  Budgetary and Policy Context for R&D in FY 
2008
• Pharmaceutical and Biotechnology R&D
•  Sequestered Science
Concurrent sessions
•  States’ Expanding Roles in Science and 
Technology
•  Building Science, Technology, and Innovation 
Capacity in Developing Nations
•  Surveillance, Privacy, and the Roles of Science 
and Technology
This article will report on the main points 
discussed at the policy forum.
2 AAAS analysis of Federal
 budget proposals for R&D
 in FY 2008
The Federal budget request released in the 
President’s FY 2008 budget message on February 
5, 2007, was $2.902 trillion, with a Federal R&D 
budget of $143 bil l ion. This is a 1.3 percent 
increase from FY 2007[3]. Of this, 58 percent 
(around $82.9 billion) is for defense-related R&D, 
with the remaining 42 percent (about $60 billion) 
going to non-defense R&D. The Department of 
Defense (DoD) R&D budget accounts for about 
95 percent of the defense-related R&D budget. 
The total represents a 1.0 percent increase from 
the previous f iscal year’s budget of $78.996 
billion. The budget for weapons development in 
particular increased 5.5 percent, to $68.1 billion. 
On the other hand, the science and technology 
budget including DoD basic and applied research 
is on a downward trend, falling 20.1 percent 
to $10.9 bi l l ion. (However, the science and 
technology budget accounts for only about 14 
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percent of the DoD R&D budget.)
AAAS R&D Budget and Policy Program Director 
Kei Koizumi reported that because of the Bush 
Administration’s goal of erasing the deficit and 
balancing the budget by 2012, the Federal R&D 
budget as whole, with the exception of budget 
related to the American Competitiveness Initiative 
(ACI), will be cut in FY 2008, as it was in FY 
2007. In concrete terms, high priority is still given 
to target organizations in the ACI’s second year, 
the U.S. Department of Energy Office of Science 
(DOE-OS), the National Science Foundation 
(NSF), and the National Institute of Standards 
and Technology (NIST) (laboratory portion), 
while the R&D budgets of other organizations 
remain the same or decrease. Even the National 
Institutes of Health (NIH) are down 1.2 percent. 
Furthermore, it is strikingly clear that while 
the basic and applied research budget is falling, 
the development budget is rising. Within the 
Federal R&D budget, basic research is down 0.2 
percent ($28.2 billion), applied research is down 
4 percent ($27.1 billion), but the development 
budget is up 2.9 percent ($82.8 billion). The 
increase in the DoD development budget has a 
major influence on this. (See Figures 1 and 2.)
Figure 1 : Percent change (from FY 2007) in FY 2008 R&D budget requests of various agencies
From Kei Koizumi, “Federal R&D Investments in the FY 2008 Budget”
Figure 2 : R&D budgets (FY 1976–2008)
From Kei Koizumi, “Federal R&D Investments in the FY 2008 Budget”
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In addition, interest in cl imate change is 
rising, and even though President Bush’s positive 
environmental policy, FY 2008 expenditures for 
the Climate Change Science Program (CCSP) are 
down 7.4 percent. According to Mr. Koizumi, this 
is because of the lower budget for NASA, which is 
the largest sponsor of climate change science.
3 Science and technology
 issues facing the USA
3-1 Speech by John H. Marburger, Science
 Advisor to the President
This was Mr. Marburger’s s ix th keynote 
address. He spoke about issues facing the US 
science and technology community and trends in 
the Federal R&D budget. His main points were as 
follows.
•  Diverse research funding sources and new business 
models required by universities
The NIH’s R&D budget doubled over the five 
years ending in FY 2003, bringing about an 
increase in the number of researchers. It will 
be difficult to maintain this rapidly expanded 
number of researchers using the conventional 
business model. Today, with competition for 
shares of the Federa l budget intensi f y ing, 
university research is beginning to diversify 
funding sources by turning to new business 
models such as building new relationships with 
private-sector sponsors. The Federal Government 
is encouraging such changes. Furthermore, 
future Federal R&D budgets are not expected 
to grow rapidly enough to meet the expanding 
scale of research. Further examination of mutual 
collaboration among Federal, state, and private 
funding is necessary.
•  Concern over and government action to mitigate 
the negative impacts of security measures
As for the negat ive impacts of secur it y 
measures on science since the 9/11 terrorist 
attacks, the situation regarding the issuing of 
student visas has greatly improved. However, 
serious issues remain, including the clumsy visa 
process for visiting scientists, implementation 
of an excessive export control regime, over-
regulation of dual-use bioscience, and security 
measures at national laboratories that sti f le 
user programs. At the same time, however, the 
government has formed numerous interagency 
committees to address the issues and seek 
solutions. For example, the National Science 
Advisory Board for Biosecurity (NSABB) formed 
in 2004 (in April 2007 it published a report 
entitled “Proposed Strategies for Minimizing the 
Potential Misuse of Life Sciences Research”) is 
working on the problem of dual-use bioscience 
by examining guidel ines on restr icting the 
publication of scientific information that requires 
cautious handling. Furthermore, the Department 
of Commerce is also working on the problem of 
export regulations. The media should pay more 
attention to these efforts.
•  Efforts directed towards new science and technology 
benchmarks: a “science of science policy”
In 2005 in this policy forum, I argued that 
the ratio of Federal R&D budget to GDP is not 
necessarily an effective indicator of a nation’s 
science strength and that a new “science of 
s c i e nce po l i c y ” w i t h mor e qu a nt i t a t i ve 
benchmarks is necessary. In response, the NSF 
launched a “science of science policy” program 
inside the USA. I am also impressed by the fact 
that the OECD has taken up the discussion 
internationally[4].
• Criticism of the AAAS budget analysis
In the AAAS report on the FY 2008 Federal 
budget, there is an important fai lure in the 
treatment of earmarks*2. The report states that 
there would be steep cuts in the FY 2008 DoD 
science and technology (S&T) programs (20.1 
percent from the previous year). (See Chart 1.) 
This report, however, does not accurately reflect 
recent debate on earmarks. It misinforms the 
readers of the AAAS report, which is widely used 
as an authoritative reference of the budget.
Last year in this policy forum as well, I pointed 
out that earmarks had rapidly increased during 
the past five years, to the point where it now 
threatens the missions of the agencies whose 
funds have been directed toward purpose that 
do not support the agency workplans. I urged 
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the AAAS to work with the White House Office 
of Science and Technology (OSTP) and the White 
House Office of Management and Budget (OMB) 
to develop a mutually comprehensible approach 
to the problem of taking earmarks into account 
in analyzing the annual science budgets. Despite 
this, the AAAS has done nothing to correct its 
practice.
*Author’s note: The reason the DoD science and 
technology (S&T) budget changed so much 
is because earmarks were removed based on 
the Bush Administration’s earmarks reform. 
It is a mistake, however, to simply interpret 
that as a drastic cut in the DoD science 
and technology budget. There were many 
cases within the DoD earmarks of projects, 
such as diabetes research, that cannot be 
regarded as research that the DoD should 
be undertaking. Cutting such items does 
not necessarily mean that DoD’s essential 
R&D budget was cut. Earmark reform is a 
course correction that cuts unnecessary 
earmarks and provides the relevant agencies 
with budgets for the important research 
that they should be doing. The gist of Mr. 
Marburger’s criticism of the AAAS analysis is 
probably that this point was not sufficiently 
considered.
3-2 Issues in pharmaceutical and
 biotechnology R&D
One of the three plenary sessions at this 
year’s forum covered “Pharmaceutica l and 
Biotechnology R&D.” This session included a 
description of the current situation and papers 
discussing problems in policy challenges for 
universities, corporations, and research institutes 
pertaining to productivity and innovation in 
pharmaceutical-related R&D, intellectual property 
rights and their effects on R&D, conf licts of 
interest in biomedical research and policy and 
ethical challenges in clinical tr ials. Will iam 
Haseltine, Chairman of Haseltine Global Health 
LLC., gave an overview of the pharmaceutical 
industry, discussing the fact that the number of 
new drugs approved versus R&D investment has 
declined markedly. He blamed the stance of major 
corporations that are developing products for 
vast markets rather than with the aim of curing 
disease. He indicated that in corporations the 
ability to tie ideas to products is being interfered 
with.
Regarding the issue of productivity in the 
biomedical field, Scott Stern of Northwestern 
University pointed out the following paradoxes. 
(i) Despite enormous investment, the number 
of FDA approvals of drugs and biomedical 
agents is still about the same as in the 1980s*3, 
(i i) despite the dramatic scienti f ic progress 
of the last 30 years (from genetics to system 
bio log y) , mos t ther apies a nd t reatment s 
are based on older science and tradit ional 
technologies, (iii) although the biotechnology 
industry includes thousands of large and small 
companies, most therapies are commercialized 
by major pharmaceutical companies under 
the conventional FDA paradigm. Regarding 
experiments on rapidly developing tailor-made 
medicine, Mr. Stern pointed out that regulatory 
frameworks are not keeping pace and argued 
for the necessity of reforming the regulatory 
process*3.
John M. Engel of the law firm Engel & Novitt 
d i s c u s s ed t he i mpor t a nt ro le p l ayed by 
intellectual property rights (IPRs) in promoting 
biomedical R&D. He emphasized that IPRs are 
becoming increasingly important in private-sector 
R&D because they are both an essential driving 
force for innovation that enables private-sector 
companies to obtain returns on their investments 
as well as effective safety nets that ease high 
risks.
In addition, Deborah A. Zarin of the National 
Library of Medicine discussed public policy 
and ethical problems in conducting clinical 
trials. Of more than 40,000 clinical trials today 
currently underway, 65 percent involve drugs. 
Many volunteers participate in trials sponsored 
by the pharmaceutical industry. However, trials 
may be oriented towards obtaining results rather 
than towards carrying out accurate scientific 
experiments, raising questions such as how to 
protect volunteers from improper risks, how to 
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decide who has access to the results, and how 
to verify that the results are accurately assessed. 
Moreover, the results of most clinical trials go 
unpublished, and data that are published may be 
hard to find or contain errors. She pointed out 
that these are both ethical and scientific problems 
and argued that policy responses are necessary.
3-3 Sequestered science:
 (issues regarding concealing and
 revealing scientific information)
The sequestering of scientific information, the 
question of whether all science and technology 
information should be published, was discussed 
from the perspectives of information sharing, 
disclosure, and management. Wendy Wagner 
of the University of Texas indicated that she 
thinks that while sequestering information for 
reasons such as protecting research progress 
or intellectual property, protecting privacy, or 
guarding from terrorist risks is not improper, 
disclosure is strongly required when risks to 
public health are involved, so guidelines that 
will function effectively in the real world are 
necessar y. Myron Har r ison, Sen ior Hea lth 
Advisor at Exxon Mobil Corp., indicated that 
he believes that appropriate measures must 
be taken to ensure that confidential business 
in formation does not harm to the publ ic’s 
health. Furthermore, he used the example of 
the American Chemical Council’s Long-range 
Research Initiative (LRI; research on the long-
term effects of chemicals on human health and 
the environment), which has the right to release 
without permission any information regarding 
risks to the public discovered by LRI researchers. 
He stated that publishing all results is essential 
to improving the quality of research, and LRI 
is a good model of that. (Mr. Harrison defines 
“sequestered science” as “scientific results that 
are not readily available to the public.”)
3-4 States’ expanding roles in science and
 technology
One of this year’s concurrent session themes 
was “States’ Expanding Roles in Science and 
Technology.” Examples of actions by New Mexico, 
Pennsylvania, Cal i fornia, and Arizona were 
introduced, and the role of states in scientific and 
technological progress and the proper form for 
regional cooperation were discussed.
Thomas Bowles, Science Advisor to the 
Governor of New Mexico, indicated that his 
state is home to science and technology centers 
at several major Federal facilities, such as Los 
A lamos and Sandia Nat iona l Laborator ies, 
Phillips Laboratory, and White Sands Missile 
Range, with an annua l R& D budget of $ 6 
bil l ion. He reported that the state has long-
term R&D investment and incentive policies in 
its strong areas of aerospace, biology, energy, 
and IT, and works at the state level to promote 
innovation. He emphasized the significance of 
science and technology policy at the state level 
as an element driving innovation in New Mexico, 
saying, “We have the resources, but have lacked a 
plan and the commitment to make the necessary 
investments.”
In addit ion, Susan Hackwood, Executive 
Director of the California Council on Science 
and Technology (CCST), described how the non-
profit CCST provides valuable advice to the State 
Governor and the Federal Government. Modeled 
on the National Research Council (NRC), the 
CCST was founded in 1988. It col laborates 
widely with California universities, research 
institutes, and industry, engaging in a variety of 
initiatives to contribute to the state economy. 
Education is another of its primary activities. The 
CCST includes the California Teacher Advisory 
Counci l (Cal TAC), which establ ishes task 
forces to develop human resources in science 
and mathematics education. Ms. Hackwood 
also described trends and issues in science and 
technology in California.
In the USA, State Governments have developed 
science and technology strategies to improve 
science education, support innovation and to 
invest in R&D to ensure the development of the 
state economies. The role of State Governments 
in the development of science and technology in 
the states has therefore been significant. With the 
Federal R&D budget stagnating, the role of states 
is growing larger through efforts to promote 
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further collaboration among regional industry 
and to prepare and improve environments 
s u p p o r t i n g  c r e a t i v i t y  a n d i n n o v a t i o n . 
Furthermore, as can be seen in Cali fornia’s 
active efforts to tackle environmental issues, in 
some cases State Governments are proactively 
taking the place of the Federal Government 
in addressing global problems. This is a major 
change of direction.
3-5 Other themes
Other sessions took up the themes of “Building 
Science, Technology, and Innovation Capacity in 
Developing Nations” and “Surveillance, Privacy, 
and the Roles of Science and Technology.”
The session on developing nations discussed 
cases such as the World Bank’s program on 
building science, technology, and innovation 
capacity and initiatives in Latin America. In 
addition, Anny Wong of RAND gave an overview 
of the results of the Global Technology Revolution 
2020[7]. This was a survey of global technology 
trends ranking the ability of 29 countries to 
acquire and implement 16 key technology 
applications.
The theme related to surveillance and privacy 
covered national security issues, which were 
a major topic in previous forums. This year’s 
subjects for discussion were narrowed down to 
surveillance technologies and privacy and social 
issues. Content included discussion of trends 
in counterterrorism through information and 
privacy protection technology.
4 Conclusion
This year’s policy forum was held amidst strong 
public interest in the actions of candidates in the 
coming presidential election and the haggling 
of President Bush and Congress surrounding 
the US military in Iraq. Attendees at the forum 
were most interested in responses to the trend 
of a declining Federal R&D budget. How to 
maintain and develop research activities when 
budgets related to defense development and 
ACI were being given a high priority while 
the R&D budgets of other organizations were 
static or declining was a common subject in 
the discussions in various the sessions on the 
role of states in science, problems facing the 
pharmaceutical industry, and so on.
This year’s forum did not hold a special session 
to discuss environmental issues, in which there 
was growing interest in Japan after President 
Bush announced the goal of cutting gasoline use 
20 percent over the next 10 years in his January 
2007 State of the Union Address and showed 
signs of aggressively addressing climate change. 
However, clean energy was one of the themes 
discussed in last year’s forum, and on April 28 
the AAAS Board of Directors released a statement 
on their sense of crisis regarding climate change 
and distributed it at the forum. The AAAS thus 
indicated that it stil l has a strong interest in 
environmental issues[8].
By br i ng i ng key people i n sc ience and 
technology policy, such as Presidential Science 
Advisor Marburger to meet with the entire 
scientific community, the AAAS forum plays a 
historically significant role. It is likely to continue 
to play this role in the future. It will remain very 
meaningful to continue Japanese participation 
in these important policy discussions as a way 
of gaining an understanding of the major issues 
related to US science and technology policy.
Acknowledgments
The author wishes to express his heartfelt 
thanks to Counselor Masami Watanabe of 
the Embassy of Japan in the United States of 
America and Dr. Suguru Ishiguro, Director of the 
Washington, DC, Office of the Japan Science and 
Technology Agency for their valuable advice in 
the writing of this article.
Glossary
*1 The AAAS is the world’s largest non-profit 
organizat ion for scientists, engineers, 
science educators, policymakers, and so 
on, with over 140,000 members. It is well-
known as the publ isher of the journal 
Science.
*2 E a r m a rk s d i f fe r f r om comp et i t i ve l y 
selected funds in that they are selected 
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by debate over their intended use. They 
have increased rapidly in the past few 
years and are widely used to bring pork-
barrel funds to the districts of members 
of Congress. The lack of transparency in 
the process and the way they can interfere 
with funding mechanisms for important 
research are seen as problems with in 
the Administration. In his January 2007 
State of the Union Address, President 
Bush proposed comprehensive reform to 
make the earmark process transparent 
and accountable through steps such as 
making all earmark information available 
to Congress and cutting earmark funding 
in half[5]. The funding resolution passed 
in February 2007 included a moratorium 
on earmarks that temporar i ly froze al l 
earmarks. As part of the reform, all future 
earmarks will probably be more carefully 
selected. According to the OMB, which is 
building a database on earmarks, in FY 2005 
alone, they numbered 13,497 for over $19 
billion. The DoD accounted for more than 
half that number.
*3 The repor t “Innovation or Stagnation: 
Challenge and Opportunity on the Critical 
Path to New Medical Products” released 
by the US Food and Drug Administration 
(FDA) in March 2004 pointed out similar 
issues[6]. It indicated that the number of 
applications for approval of new drugs has 
fallen dramatically in recent years, and that 
despite the expectations of the biomedical 
revolution, new scientific discoveries are 
not being converted to the development 
of safe and effective drugs. As causes, the 
report cites today’s more chal lenging, 
inefficient, and expensive drug development 
path, along with the failure of the applied 
science required for drug development to 
keep pace with the marvelous progress of 
basic science. The report states that new 
scientific and technical methods such as 
animal or computer-based predictive models, 
biomarkers for safety and effectiveness, and 
new clinical evaluation techniques - - are 
urgently needed to improve predictability 
and efficiency along the critical path from 
laboratory concept to commercial product.
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